SS Innovations International (NASDAQ: SSII) reported record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year. The company's SSi Mantra surgical robotic system installations grew 30.4% to 30 during the quarter, contributing to a cumulative installed base of 224 systems across 12 countries as of June 30.
Gross profit rose 20% to $7.1 million, with a gross margin of 50.9%. Net loss widened to $2.7 million, or $0.01 per diluted share, from $0.3 million a year earlier. First-half revenue increased 65.6% to $25 million, with installations up 47.4% to 56. The company ended the period with $13.6 million in cash and cash equivalents and no long-term debt.
The company reported 12,272 cumulative procedures using the SSi Mantra as of June 30, including 175 telesurgeries. Notably, it recently completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India, demonstrating the system's remote capabilities.
SS Innovations expects the U.S. Food and Drug Administration (FDA) to complete its review of the company's 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027. The company also believes it can obtain European Union CE marking certification by the end of 2026. These milestones are critical for expanding into major Western markets.
"Our record revenue and continued adoption of the SSi Mantra underscore the growing demand for affordable robotic surgery solutions globally," said a company spokesperson. "We are making significant strides in regulatory approvals, which will open new markets and drive further growth."
The company's focus on cost-effective surgical robotics positions it to address the needs of healthcare systems seeking to expand access to minimally invasive procedures. With a strong balance sheet and no long-term debt, SS Innovations is well-positioned to navigate the regulatory landscape and scale its operations.
For more information on the company's latest news and updates, visit the newsroom at https://ibn.fm/SSII.
About SS Innovations International: SS Innovations International (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company's product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
